12:00 AM
Nov 01, 2016
 |  BC Innovations  |  Distillery Therapeutics



Patient sample and mouse studies suggest promoting ID2 expression or inhibiting TCF4 could help treat PGC-1α-deficient metastatic melanoma. In primary tumor samples from 68 melanoma patients, invasive tumor pathology was associated...

Read the full 153 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$35 USD
More Info >